Cure in advanced renal cell cancer: Is it an achievable goal?

Dhanusha Sabanathan, John J. Park, Manuel Marquez, Louise Francisco, Natalie Byrne, Howard Gurney

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background. Immunotherapy has historically been of interest in the management of metastatic renal cell cancer (mRCC) because of its relative chemoresistance and the reproducible but low incidence of spontaneous remission in metastatic disease. Recently, targeted immunotherapies in the form of checkpoint inhibitors have shown durable responses in approximately 20%– 30% of patients with solid tumors, with a much more acceptable side-effect profile. Anti-programmed death receptor 1 (PD-1)/ programmed death receptor ligand 1 antibodies rely on the presence of host T cells in the tumor microenvironment to be stimulated in order to activate an antitumor response. The presence of tumor antigens augments this stimulation. This has led to further research into combination therapy with anti-PD-1 inhibitors and radiotherapy, chemotherapy, or targeted therapy with the aim of increasing the response rate to these agents. Materials and Methods. We describe three cases of patients with mRCC treated with anti-PD-1 antibody therapy in combination with targeted therapy (bevacizumab), anti-cytotoxic T lymphocyte antigen 4 therapy (ipilimumab), or radiotherapy. We perform a comprehensive literature review on combination immunotherapy and the scope for the future. Results. Two patients had a complete clinical response within 3 months of commencing treatment. The third patient had a further significant response to radiotherapy outside the field of treatment after initial response to anti-PD-1 therapy, which lasted for over 12 months. Conclusion. We are now in the era of immunotherapy with promising results in select patients. However, the number of complete remissions with single agents are low. This report demonstrates the potential for combination therapy in mRCC to produce complete responses and improved survival rates. Whether these results equate to cure in a subset of patients requires longer follow-up. Further evaluation of dosing regimens, sequencing methods, and biomarkers to select patient population is required to advance this treatment strategy.

LanguageEnglish
Pages1470-1477
Number of pages8
JournalOncologist
Volume22
Issue number12
DOIs
Publication statusPublished - 1 Dec 2017

Fingerprint

Renal Cell Carcinoma
Death Domain Receptors
Immunotherapy
Therapeutics
Radiotherapy
CTLA-4 Antigen
Spontaneous Remission
Tumor Microenvironment
Antibodies
Neoplasm Antigens
Survival Rate
Biomarkers
Ligands
T-Lymphocytes
Drug Therapy
Incidence

Keywords

  • Combination therapy
  • Complete response rate
  • Immunotherapy
  • Renal cell carcinoma
  • Targeted therapy

Cite this

Sabanathan, Dhanusha ; Park, John J. ; Marquez, Manuel ; Francisco, Louise ; Byrne, Natalie ; Gurney, Howard. / Cure in advanced renal cell cancer : Is it an achievable goal?. In: Oncologist. 2017 ; Vol. 22, No. 12. pp. 1470-1477.
@article{b5a5ca85db9b46ca81e98252d0a99480,
title = "Cure in advanced renal cell cancer: Is it an achievable goal?",
abstract = "Background. Immunotherapy has historically been of interest in the management of metastatic renal cell cancer (mRCC) because of its relative chemoresistance and the reproducible but low incidence of spontaneous remission in metastatic disease. Recently, targeted immunotherapies in the form of checkpoint inhibitors have shown durable responses in approximately 20{\%}– 30{\%} of patients with solid tumors, with a much more acceptable side-effect profile. Anti-programmed death receptor 1 (PD-1)/ programmed death receptor ligand 1 antibodies rely on the presence of host T cells in the tumor microenvironment to be stimulated in order to activate an antitumor response. The presence of tumor antigens augments this stimulation. This has led to further research into combination therapy with anti-PD-1 inhibitors and radiotherapy, chemotherapy, or targeted therapy with the aim of increasing the response rate to these agents. Materials and Methods. We describe three cases of patients with mRCC treated with anti-PD-1 antibody therapy in combination with targeted therapy (bevacizumab), anti-cytotoxic T lymphocyte antigen 4 therapy (ipilimumab), or radiotherapy. We perform a comprehensive literature review on combination immunotherapy and the scope for the future. Results. Two patients had a complete clinical response within 3 months of commencing treatment. The third patient had a further significant response to radiotherapy outside the field of treatment after initial response to anti-PD-1 therapy, which lasted for over 12 months. Conclusion. We are now in the era of immunotherapy with promising results in select patients. However, the number of complete remissions with single agents are low. This report demonstrates the potential for combination therapy in mRCC to produce complete responses and improved survival rates. Whether these results equate to cure in a subset of patients requires longer follow-up. Further evaluation of dosing regimens, sequencing methods, and biomarkers to select patient population is required to advance this treatment strategy.",
keywords = "Combination therapy, Complete response rate, Immunotherapy, Renal cell carcinoma, Targeted therapy",
author = "Dhanusha Sabanathan and Park, {John J.} and Manuel Marquez and Louise Francisco and Natalie Byrne and Howard Gurney",
year = "2017",
month = "12",
day = "1",
doi = "10.1634/theoncologist.2017-0159",
language = "English",
volume = "22",
pages = "1470--1477",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "12",

}

Sabanathan, D, Park, JJ, Marquez, M, Francisco, L, Byrne, N & Gurney, H 2017, 'Cure in advanced renal cell cancer: Is it an achievable goal?', Oncologist, vol. 22, no. 12, pp. 1470-1477. https://doi.org/10.1634/theoncologist.2017-0159

Cure in advanced renal cell cancer : Is it an achievable goal? / Sabanathan, Dhanusha; Park, John J.; Marquez, Manuel; Francisco, Louise; Byrne, Natalie; Gurney, Howard.

In: Oncologist, Vol. 22, No. 12, 01.12.2017, p. 1470-1477.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Cure in advanced renal cell cancer

T2 - Oncologist

AU - Sabanathan, Dhanusha

AU - Park, John J.

AU - Marquez, Manuel

AU - Francisco, Louise

AU - Byrne, Natalie

AU - Gurney, Howard

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background. Immunotherapy has historically been of interest in the management of metastatic renal cell cancer (mRCC) because of its relative chemoresistance and the reproducible but low incidence of spontaneous remission in metastatic disease. Recently, targeted immunotherapies in the form of checkpoint inhibitors have shown durable responses in approximately 20%– 30% of patients with solid tumors, with a much more acceptable side-effect profile. Anti-programmed death receptor 1 (PD-1)/ programmed death receptor ligand 1 antibodies rely on the presence of host T cells in the tumor microenvironment to be stimulated in order to activate an antitumor response. The presence of tumor antigens augments this stimulation. This has led to further research into combination therapy with anti-PD-1 inhibitors and radiotherapy, chemotherapy, or targeted therapy with the aim of increasing the response rate to these agents. Materials and Methods. We describe three cases of patients with mRCC treated with anti-PD-1 antibody therapy in combination with targeted therapy (bevacizumab), anti-cytotoxic T lymphocyte antigen 4 therapy (ipilimumab), or radiotherapy. We perform a comprehensive literature review on combination immunotherapy and the scope for the future. Results. Two patients had a complete clinical response within 3 months of commencing treatment. The third patient had a further significant response to radiotherapy outside the field of treatment after initial response to anti-PD-1 therapy, which lasted for over 12 months. Conclusion. We are now in the era of immunotherapy with promising results in select patients. However, the number of complete remissions with single agents are low. This report demonstrates the potential for combination therapy in mRCC to produce complete responses and improved survival rates. Whether these results equate to cure in a subset of patients requires longer follow-up. Further evaluation of dosing regimens, sequencing methods, and biomarkers to select patient population is required to advance this treatment strategy.

AB - Background. Immunotherapy has historically been of interest in the management of metastatic renal cell cancer (mRCC) because of its relative chemoresistance and the reproducible but low incidence of spontaneous remission in metastatic disease. Recently, targeted immunotherapies in the form of checkpoint inhibitors have shown durable responses in approximately 20%– 30% of patients with solid tumors, with a much more acceptable side-effect profile. Anti-programmed death receptor 1 (PD-1)/ programmed death receptor ligand 1 antibodies rely on the presence of host T cells in the tumor microenvironment to be stimulated in order to activate an antitumor response. The presence of tumor antigens augments this stimulation. This has led to further research into combination therapy with anti-PD-1 inhibitors and radiotherapy, chemotherapy, or targeted therapy with the aim of increasing the response rate to these agents. Materials and Methods. We describe three cases of patients with mRCC treated with anti-PD-1 antibody therapy in combination with targeted therapy (bevacizumab), anti-cytotoxic T lymphocyte antigen 4 therapy (ipilimumab), or radiotherapy. We perform a comprehensive literature review on combination immunotherapy and the scope for the future. Results. Two patients had a complete clinical response within 3 months of commencing treatment. The third patient had a further significant response to radiotherapy outside the field of treatment after initial response to anti-PD-1 therapy, which lasted for over 12 months. Conclusion. We are now in the era of immunotherapy with promising results in select patients. However, the number of complete remissions with single agents are low. This report demonstrates the potential for combination therapy in mRCC to produce complete responses and improved survival rates. Whether these results equate to cure in a subset of patients requires longer follow-up. Further evaluation of dosing regimens, sequencing methods, and biomarkers to select patient population is required to advance this treatment strategy.

KW - Combination therapy

KW - Complete response rate

KW - Immunotherapy

KW - Renal cell carcinoma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85038599230&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2017-0159

DO - 10.1634/theoncologist.2017-0159

M3 - Article

VL - 22

SP - 1470

EP - 1477

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 12

ER -